Varian Provides Update on Proposed Sirtex Acquisition

Thursday, June 14, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

PALO ALTO, Calif., June 14, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced it received notification from Sirtex

Medical Limited (Sirtex) on June 14, 2018 that its board has determined that the proposal from CDH Investments and China Grand Pharmaceutical and Healthcare Holdings Limited (CDH-CGP Proposal) is a Superior Proposal
as defined in the Scheme Implementation Deed between Sirtex and Varian (Varian Scheme). Consistent with Varian's prior announcements, Varian informed Sirtex that Varian will not be providing a counter proposal. Sirtex has consequently terminated the Varian Scheme and confirmed that it is required to pay a Reimbursement Fee of approximately A$16 million to Varian.

"Varian is very disciplined in its business development approach and we do not see value beyond the A$28 price per share we offered for Sirtex," said Dow Wilson, president and chief executive officer of Varian.  "While disappointed with this decision, Varian's long-term strategy has not changed. We remain focused on becoming a global leader in multi-disciplinary, integrated cancer care solutions; expanding the addressable markets that Varian can impact; and growing and creating sustainable value for our company and our shareholders."

About Varian

Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.

Press Contact

Mark PlungyDirector, Public Relations+1 (650) 424-5630 mark.plungy@varian.com

Investor Relations Contact

J. Michael BruffSenior Vice President, Investor Relations+1 (650) 424-5163 investors@varian.com

 

Cision View original content:http://www.prnewswire.com/news-releases/varian-provides-update-on-proposed-sirtex-acquisition-300666424.html

SOURCE Varian



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store